Literature DB >> 22815099

Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.

Roger Feldman1, Félix Lobo.   

Abstract

We take on two subjects of controversy among economists-advertising and trademarks-in the context of the market for generic drugs. We outline a model in which trademarks for drug names reduce search costs but increase product differentiation. In this particular framework, trademarks may not benefit consumers. In contrast, the generic names of drugs or "International Nonproprietary Names" (INN) have unquestionable benefits in both economic theory and empirical studies. We offer a second model where advertising of a brand-name drug creates recognition for the generic name. The monopoly patent-holder advertises less than in the absence of a competitive spillover.

Mesh:

Substances:

Year:  2012        PMID: 22815099     DOI: 10.1007/s10198-012-0414-7

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  13 in total

1.  Barriers to entry in the Canadian pharmaceutical industry. Comments, clarification and extensions.

Authors:  P K Gorecki
Journal:  J Health Econ       Date:  1987-03       Impact factor: 3.883

2.  Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry.

Authors:  J J McRae; F Tapon
Journal:  J Health Econ       Date:  1985-03       Impact factor: 3.883

3.  Post-patent barriers to entry in the pharmaceutical industry.

Authors:  F M Scherer
Journal:  J Health Econ       Date:  1985-03       Impact factor: 3.883

4.  The effect of generic competition on the price of brand-name drugs.

Authors:  Joel Lexchin
Journal:  Health Policy       Date:  2004-04       Impact factor: 2.980

5.  Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.

Authors:  H Grabowski; J Vernon
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

6.  Similarity as a risk factor in drug-name confusion errors: the look-alike (orthographic) and sound-alike (phonetic) model.

Authors:  B L Lambert; S J Lin; K Y Chang; S K Gandhi
Journal:  Med Care       Date:  1999-12       Impact factor: 2.983

7.  Advertising and generic market entry.

Authors:  Ingrid Königbauer
Journal:  J Health Econ       Date:  2006-10-02       Impact factor: 3.883

8.  The ongoing regulation of generic drugs.

Authors:  Richard G Frank
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

9.  EXPERT committee on the unification of pharmacopoeias; report on the sixth session, New York City, N.Y. , 20-29 April 1950.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1950-10

10.  Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data.

Authors:  Maria-Isabel Farfan-Portet; Carine Van de Voorde; France Vrijens; Robert Vander Stichele
Journal:  Eur J Health Econ       Date:  2012-03-18
View more
  1 in total

Review 1.  Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Authors:  María-Isabel Farfan-Portet; Sophie Gerkens; Isabelle Lepage-Nefkens; Irmgard Vinck; Frank Hulstaert
Journal:  Eur J Health Econ       Date:  2013-11-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.